Kanaph Therapeutics Inc. (KOSDAQ:0082N0)

South Korea · Delayed Price · Currency is KRW

15,690

+360 (2.35%)

At close: Aug 11, 2026

-76.96% (1Y)

Market Cap	204.25B
Revenue	n/a
Net Income	n/a
EPS	n/a
Shares Out	13.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	111,606
Open	15,330
Previous Close	15,330
Day's Range	15,010 - 16,940
52-Week Range	9,170 - 70,000
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Kanaph Therapeutics

Kanaph Therapeutics Inc., a biotech company, engages in drug development activities that include drug discovery and early-stage clinical trials in South Korea and the United States. The company's therapeutic platform includes bi-specific antibodies, Fc-fusions, and small molecules. It develops KNP-101, a FAP-targeted interleukin-12 cytokine, which is in preclinical stage for the treatment of solid tumors with an immunosuppressive tumor microenvironment; KKNP-301, a bispecific Fc-fusion protein that combines a C3b blocker and a VEGF blocker ther... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2019

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 0082N0

Full Company Profile